Tag Archives: Partnering

Life Science Leader Asks: What Areas Are Often Overlooked by Academics Turned Biotech Entrepreneurs?

Life Science Leader

In my third installment of a four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, he shared missteps made by academics aspiring to become entrepreneurs and also offered up some advice on partnering with VCs. Check out my interview, which will include lessons that won’t be a part of his 2015 BIO International Convention session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, (June 16, 3:30 p.m.-4:45 p.m., room 105AB) Here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Partnering Trends in Latin America


If phonetics were the only driver, BRIC would be CRIB. But life sciences drug-related deal-making and partnering growth in Brazil and the rest of Latin America provide good reason to put the “B” in front. Traditional partnerships (i.e. excluding M&A and early venture funding) where a Latin American company served as the ‘seller’ or ‘out-licensor’ doubled per year from 2009/2010 to 2012. While there was a pullback in 2013, overall growth from 2009/2010 to 2013 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Protecting your IP Overseas


According to the World Intellectual Property Organization (WIPO), nearly 100,000 biotechnology and pharmaceutical patent applications are filed worldwide each year, and the trend appears to be rising. As you’ve likely experienced, filing patent applications can be very complex, with different laws, deadlines and languages requiring highly technical translators for most countries in which you’re seeking protection. As a result, companies seeking IP protection often outsource their domestic and foreign patent filings to service providers to Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

FedEx’s Meet-and-Greet with Marshall Faulk during the BIO International Convention

Marshall Faulk

We know that the BIO International Convention consists of a full agenda with a plethora of activities.  Whether you are an exhibitor, panel participate, company or a one-on-one meeting delegate, why not take time from your busy schedule to learn about the industry’s largest cost savings program known as BIO Business Solutions®. Last year, BIO saved more than 2,800 life science companies nationwide $135,000,000 in aggregate on their 2013 purchases of products and services through Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

What Do Large Pharma and Biotech Companies Want to Buy?


Out-licensors are always asking this fundamental question: what do in-licensors want? “In-licensors” extend far beyond the top 50 companies. At BIO 2013, there were about 1000 drug R&D companies. Approximately 20% were in-licensors and 80% were out-licensors, according to their BIO One-on-One Partnering profiles. According to Thomson Reuters Recap, there were  a little over 700 licensing and joint venture deals in 2013, involving about 500 buy-siders/licensees. For more on buy-side deal trends, see our recorded webinar with Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,